Condition Directory

Heart Failure clinical trials

Directory of U.S. ClinicalTrials.gov public records for Heart Failure. Browse Heart Failure recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

375

Shown on this page

Local recruiting

Local phase groups

The trial list below is retrieved from the live ClinicalTrials.gov search API for Heart Failure. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 375 matching trials for Heart Failure.

Indexed local directory records.

Phase distribution

Not applicable 170

Phase 2 40

Phase 3 28

Phase 4 27

Phase 1 17

Early Phase 1 3

Top locations

New York, New York 74 Boston, Massachusetts 65 Philadelphia, Pennsylvania 61 Dallas, Texas 59 St Louis, Missouri 55 Houston, Texas 55

Top sponsors

Abbott Medical Devices 14 Brigham and Women's Hospital 13 VA Office of Research and Development 10 Mayo Clinic 8 CVRx, Inc. 7 Yale University 7

Top therapies

Anakinra 3 CardioMEMS HF System 3 Alleviant ALV1 System 2 BAROSTIM NEO® System 2 Barostim™ System 2 Beta blocker 2

Indexed official records

Open in full search

Conditions: Heart Failure
Interventions: High Dose PF-07328948, Low Dose PF-07328948, Medium Dose PF-07328948, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 28
States / cities: Beverly Hills, California • Lake Forest, California • Santa Maria, California + 17 more

Conditions: Heart Failure
Interventions: Baxdrostat and dapagliflozin, Placebo and dapagliflozin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 11,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 194
States / cities: Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 173 more

Conditions: Chronic Lymphocytic Leukaemia, Heart Failure
Interventions: Acalabrutinib, Investigator's choice of treatment; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Placebo, empagliflozin, vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 107
States / cities: Mobile, Alabama • Montgomery, Alabama • Beverly Hills, California + 91 more

Conditions: Heart Failure
Interventions: empagliflozin, placebo, vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 94
States / cities: Mobile, Alabama • Chula Vista, California • Orange, California + 81 more

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Placebo suspension, Placebo tablet, Vericiguat suspension, Vericiguat tablet; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Heart Failure, Socioeconomic Adversity
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Failure
Interventions: BMS-986435, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 31
States / cities: Birmingham, Alabama • Lakewood, Colorado • Jacksonville, Florida + 21 more

Conditions: Heart Failure
Interventions: Control non-intervention; PAC without filter, PAC provision at hospital discharge; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Aortic Diseases, Atrial Fibrillation, Cardiovascular Diseases, Congenital Heart Disease, Heart Failure, Ischemic Heart Disease, Metabolic Cardiomyopathy, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Ventricular Fibrillation
Interventions: MRI; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2042
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bariatric Surgery Candidate, Cardiovascular Diseases, Heart Failure
Interventions: MRI; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atherosclerotic Disease, Cachexia, Chronic Kidney Disease(CKD), Cystic Fibrosis (CF), Diabetes, Heart Failure, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, MASH, Obesity and Obesity-related Medical Conditions, Osteopenia, Osteoporosis, Sarcopenia
Interventions: Endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

About this Heart Failure clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Heart Failure as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Heart Failure.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Heart Failure clinical trials

Filter and sort this condition

Phase distribution

Top locations

Top sponsors

Top therapies

Indexed official records

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Project 4: ACHIEVE PATHFINDER

Development of CIRC Technologies

CV Imaging of Metabolic Interventions

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

About this Heart Failure clinical trials directory page